Britannia Pharmaceuticals

More stories

• Novel asthma treatment comes closer to market

  Britannia Pharmaceuticals12 November 2004

  Dry powder synthetic surfactant which shows promise for prophylactic treatment of seasonal allergic asthma and other respiratory conditions to get further development

• Automimmune treatment for the UK

  Britannia Pharmaceuticals16 April 2004

  Novel treatment for inflammatory related diseases provides a significant alternative to other pharmaceutical therapies

• 2003 'a landmark year'

  Britannia Pharmaceuticals26 January 2004

  Britannia closes 2003 with several new partnership agreements and significant clinical progress, and aims for strategic partnerships to further develop innovative powder treatment for asthma

• Bringing drug addiction treatment to the USA

  Britannia Pharmaceuticals20 November 2003

  Lofexidine is the only non-opiate, non-addictive treatment approved in the United Kingdom used to manage withdrawal symptoms in patients undergoing opiate detoxification

• Advancing development of surgical adhesions

  Britannia Pharmaceuticals16 October 2003

  AdSurf is a synthetic surfactant - a unique formulation of the naturally occurring phospholipids dipalmitoylphosphatidycholine and phosphatidyl glycerol

More like this